Skip to content
Resources > Reports

G2 Grid Report for Financial Research - Winter 2024

AlphaSense is dedicated to providing our customers with the highest quality market and competitive intelligence. But don’t just take our word for it—we’re thrilled to announce we have been named the #1 Leader in G2’s Winter 2024 Grid® Report for Financial Research. With an overall G2 score of 95 out of 100, AlphaSense beat out all other competitors in this category.

G2’s Grid® Report is designed to highlight the voices of real Financial Research software users. Based on actual product reviews from AlphaSense users combined with third-party data, G2 analyzes and rates Financial Research software solutions to help buyers select the right vendor for their organization.

In G2’s Winter 2024 Financial Research Grid Report, you’ll find:

  • A visual representation of how AlphaSense measures up to our competitors
  • Feature Comparisons including financial information, analysis, market news, and platform basics
  • Satisfaction Ratings based on AlphaSense customers’ ratings and G2’s reviewer database

Bonus:This report also includes a breakdown of each company’s customer segments by product, as well as G2’s Market Presence score, which highlights a company’s product impact and influence in its respective category.

Explore more

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.